Cervical Squamous Intraepithelial Neoplasia 2 clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

    open to eligible females ages 21 years and up

    This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    Los Angeles, California

Our lead scientists for Cervical Squamous Intraepithelial Neoplasia 2 research studies include .

Last updated: